ABSTRACT
OBJECTIVE: To investigate p53 and c-jun oncoproteins and proliferating cell nuclear antigen (PCNA) in transitional cell urinary bladder carcinomas (TCCs) and to determine their relationships to tumour grade, stage and survival. MATERIALS AND METHODS: The expression of p53, c-jun and PCNA was studied using immunohistochemistry in formalin-fixed, paraffin-embedded tissues in a series of 110 TCCs. RESULTS: 58% of our cases were positive for p53 and 88% for c-jun. A statistically very significant correlation (p < 0.0001) was observed between p53 and c-jun (r = 0.781), p53 and PCNA (r = 0.772), c-jun and PCNA (r = 0.831) as well as between each of the two oncoproteins and the histological grade and clinical stage (p < 0.001). There was no correlation of either p53, PCNA or c-jun with clinical outcome in terms of patients survival. CONCLUSION: p53 and c-jun proteins' overexpression are strongly related to rapid tumour cell proliferation and hence with aggressive growth in urinary bladder TCC. PCNA score remains an important prognostic index in transitional cell carcinoma of the bladder.
Subject(s)
Carcinoma, Transitional Cell/genetics , Gene Expression Regulation, Neoplastic/genetics , Proliferating Cell Nuclear Antigen/biosynthesis , Proto-Oncogene Proteins c-jun/biosynthesis , Tumor Suppressor Protein p53/biosynthesis , Urinary Bladder Neoplasms/genetics , Antibodies, Monoclonal , Biopsy , Carcinoma, Transitional Cell/chemistry , Carcinoma, Transitional Cell/mortality , Carcinoma, Transitional Cell/pathology , Cell Division/genetics , Genes, jun/genetics , Genes, p53/genetics , Humans , Immunohistochemistry , Neoplasm Recurrence, Local , Proliferating Cell Nuclear Antigen/analysis , Proliferating Cell Nuclear Antigen/genetics , Proto-Oncogene Proteins c-jun/analysis , Proto-Oncogene Proteins c-jun/genetics , Survival Analysis , Tumor Suppressor Protein p53/analysis , Tumor Suppressor Protein p53/genetics , Urinary Bladder Neoplasms/chemistry , Urinary Bladder Neoplasms/mortality , Urinary Bladder Neoplasms/pathologyABSTRACT
One hundred-fourteen cervical lesions, including paraffin sections from benign, premalignant and malignant cervical tissue specimens were examined immunohistochemically for overexpression of p53 protein, using the p53 DO-1 monoclonal antibody (MoAb). p53 overexpression was observed in 66% of premalignant cervical lesions and in 90% of invasive squamous cell carcinomas. The difference in p53 positive lesions of premalignant and malignant cervical lesions was statistically very significant (p < 0.001) and the difference between CIN1 and CIN2 and CIN3 statistically significant (p < 0.01). Our results indicate that p53 overexpression may be involved at an early stage in cervical carcinogenesis.
Subject(s)
Precancerous Conditions/chemistry , Tumor Suppressor Protein p53/analysis , Uterine Cervical Neoplasms/chemistry , Antibodies, Monoclonal/immunology , Female , Humans , Immunohistochemistry , Tumor Suppressor Protein p53/immunology , Uterine Cervical Dysplasia/chemistryABSTRACT
Localization of p53 oncoprotein was investigated in 60 hepatocellular carcinomas (HCCs) from patients resident in the Northwest and Central Greece. The streptavidin-biotin complex immunoperoxidase method was performed in archival formalin-fixed, paraffin-embedded material, using the monoclonal antibody DO-1. The aim of our study was to correlate p53 expression with histological and epidemiological data. p53 overexpression in patients with serological hepatitis B or C was greater (47%) as compared to that observed in patients without these markers (p < 0.01). Morphologically normal liver tissue (NLT) and liver cell dysplasia (LCD) was recognized adjacent to HCC developing on non-alcoholic cirrhotic livers in patients with "NonA, NonB hepatitis" from between 1975-1986. NLT and LCD and p53 oncoprotein was expressed in 10% of the cases. No relationship was observed between p53 expression and tumor histological grade, patients' age and sex. These results suggest that in Northwest and Central Greece, p53 oncosupressor gene may be involved in some HCCs; it may be associated with viral chronic infection disease (HBV or HCV), and as yet with uncharacterized viruses which remain to be determined.
Subject(s)
Carcinoma, Hepatocellular/metabolism , Liver Neoplasms/metabolism , Tumor Suppressor Protein p53/metabolism , Adult , Aged , Aged, 80 and over , Antibodies, Monoclonal , Carcinoma, Hepatocellular/epidemiology , Carcinoma, Hepatocellular/pathology , Female , Greece , Hepatitis B/diagnosis , Hepatitis B/epidemiology , Hepatitis B/metabolism , Hepatitis C/diagnosis , Hepatitis C/epidemiology , Hepatitis C/metabolism , Hepatitis E/metabolism , Humans , Immunoenzyme Techniques , Liver/pathology , Liver Cirrhosis/metabolism , Liver Neoplasms/epidemiology , Liver Neoplasms/pathology , Male , Middle Aged , Prevalence , Serologic TestsABSTRACT
Immunolocalization of the bcl-2 protein was investigated in 60 hepatocellular carcinomas, 10 cholangiocarcinomas. 15 metastatic adenocarcinomas as well as in 37 non-neoplastic liver lesions. The three-step immunoperoxidase method was performed in archival, routinely processed material. bcl-2 protein was not identified either in neoplastic, dysplastic or normal hepatocytes, whereas it was observed in bile ductules and small bile duct epithelia, but not in the epithelium lining large bile ducts. All cases of cholangiocarcinoma and 60% of metastatic adenocarcinomas were bcl-2 positive. bcl-2 appears to be an additional marker in distinguishing hepatocellular carcinoma from cholangiocarcinoma or metastatic adenocarcinoma. Also, bcl-2 does not seem to be involved in human liver hepatocyte survival.
Subject(s)
Carcinoma, Hepatocellular/chemistry , Cholangiocarcinoma/chemistry , Liver Neoplasms/chemistry , Liver/chemistry , Neoplasm Proteins/analysis , Precancerous Conditions/chemistry , Proto-Oncogene Proteins/analysis , Adenocarcinoma/chemistry , Adenocarcinoma/secondary , Breast Neoplasms/pathology , Colonic Neoplasms/pathology , Humans , Liver Diseases , Proto-Oncogene Proteins c-bcl-2ABSTRACT
The immunohistochemical expression of C-myc p62 oncoprotein was investigated using the immunoperoxidase method and the monoclonal antibody (Mab) MYC 1-9E10 in bone marrow paraffin sections. 180 cases of multiple myeloma (MM) were studied. C-myc expression was found to correlate well with the grade of malignancy, type of myeloma and tumor cell burden (p < 0.001). A relationship was also observed between C-myc p62 and IgA-secreting myelomas. It was found that intermediate grade myelomas are heterogeneous as far as C-myc expression is concerned. Our findings strongly suggest that C-myc might be involved in myelomutagenesis. The evaluation of its expression in MM may be helpful in determining the grade of malignancy and possibly the biological behaviour of this tumor.
